

PARTICIPATING FACULTY

Update on the Diagnosis and Treatment of Gout

This supplement to *The American Journal of Managed Care* provides information on risk factors for hyperuricemia and gout, the incidence and prevalence of these conditions, approaches to the diagnosis of gout, pharmacologic and nonpharmacologic treatments for gout, and clinical, humanistic, and economic outcomes of gout.

Faculty

Diana I. Brixner, RPh, PhD

Associate Professor and Chair
Department of Pharmacotherapy
Executive Director
Pharmacotherapy Outcomes
Research Center
University of Utah
Salt Lake City

Amy C. Cannella, MD

Assistant Professor
Section of Rheumatology and
Immunology
Nebraska Medical Center
Omaha

Mei-Jen Ho, PharmD

Fellow and MPH Candidate
Department of Pharmacotherapy
Pharmacotherapy Outcomes
Research Center
University of Utah
Salt Lake City

Andrew J. Luk, MD, MPH

Acting Chief of Rheumatology
Division of Rheumatology
University of Washington
VA Puget Sound Health Care
System
Seattle

Ted R. Mikuls, MD, MSPH

Assistant Professor
Section of Rheumatology and
Immunology
Nebraska Medical Center
Omaha

Naomi Schlesinger, MD

Director, Clinical Rheumatology
Department of Medicine
UMDNJ-Robert Wood Johnson
Medical School
New Brunswick, NJ

Peter A. Simkin, MD

Professor of Medicine
Division of Rheumatology
University of Washington
Seattle

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants report relationships with pharmaceutical companies:

■ **Diana I. Brixner, RPh, PhD**
Research/Grant Support From:
Consultation/
Speakers' Bureau For:
Bristol-Myers Squibb
Genzyme
Sanofi-Aventis
TAP
Research Support From:
Boehringer Ingelheim
Pfizer

Consultation/Speakers' Bureau For:
Abbott
Amgen
NPS
Schering Plough
Watson

■ **Ted R. Mikuls, MD, MSPH**
Consultation For:
TAP

■ **Peter A. Simkin, MD**
Speakers' Bureau For:
Fallon Medica
TAP

These participants report no financial affiliations with pharmaceutical companies:

■ **Amy C. Cannella, MD** ■ **Mei-Jen Ho, PharmD** ■ **Andrew J. Luk, MD, MPH** ■ **Naomi Schlesinger, MD**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

CONTINUING EDUCATION

Update on the Diagnosis and Treatment of Gout

GOAL

To provide participants with information about the epidemiology of hyperuricemia and gout and current approaches to diagnosis and treatment of these conditions.

TARGET AUDIENCE

This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, primary care physicians, and specialists in rheumatology.

EDUCATIONAL OBJECTIVES

After completing this continuing education activity, the participant should be able to:

- Review the epidemiology of gout.
- Describe diagnosis of gout—signs and symptoms, laboratory tests, radiologic findings.
- Discuss current and emerging treatments for gout.
- Review clinical and economic impact of gout.

CONTINUING MEDICAL EDUCATION ACCREDITATION

The University of Cincinnati College of Medicine designates this activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Release Date: November 1, 2005. Expiration Date: November 30, 2006.



CONTINUING PHARMACY EDUCATION ACCREDITATION

Pharmacy Times/Ascend Media is accredited by the Accreditation Council for Pharmacy Education (ACPE)® as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-05-021-H04. Release Date: November 1, 2005. Expiration Date: November 1, 2006.

FUNDING

This program is supported by an unrestricted educational grant from **TAP Pharmaceutical Products Inc.**

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.